Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Non-Current Liabilities data on record, last reported at $7.9 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 0.87% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, down 0.87%, while the annual FY2025 figure was $7.9 million, 0.87% down from the prior year.
  • Other Non-Current Liabilities reached $7.9 million in Q4 2025 per APLS's latest filing, up from $3.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $345.2 million in Q4 2021 and bottomed at $347000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $64.2 million, with a median of $2.7 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 99.55% in 2022, then skyrocketed 939.01% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $345.2 million in 2021, then crashed by 99.44% to $1.9 million in 2022, then grew by 19.3% to $2.3 million in 2023, then surged by 244.81% to $8.0 million in 2024, then dropped by 0.87% to $7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $7.9 million in Q4 2025, $3.3 million in Q3 2025, and $2.1 million in Q2 2025.